The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Optimer Pharmaceuticals beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted significantly. GAAP earnings per share shrank significantly.
Margins shrank across the board.
Optimer Pharmaceuticals logged revenue of $19.5 million. The nine analysts polled by S&P Capital IQ expected revenue of $18.1 million on the same basis. GAAP reported sales were 70% lower than the prior-year quarter's $64.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.02. The 10 earnings estimates compiled by S&P Capital IQ anticipated -$0.38 per share. GAAP EPS of $0.02 for Q4 were 93% lower than the prior-year quarter's $0.28 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 23.7%, much worse than the prior-year quarter. Operating margin was -155.4%, much worse than the prior-year quarter. Net margin was 5.1%, much worse than the prior-year quarter.
Next quarter's average estimate for revenue is $21.3 million. On the bottom line, the average EPS estimate is -$0.39.
Next year's average estimate for revenue is $105.9 million. The average EPS estimate is -$1.73.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 108 members out of 145 rating the stock outperform, and 37 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 34 give Optimer Pharmaceuticals a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Optimer Pharmaceuticals is outperform, with an average price target of $16.56.
- Add Optimer Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.